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patients admitted for coronary bypass surgery, valvular
surgery, or both at our institution.4,5 These patients
often have poor preoperative left ventricular function,6
unstable angina,7 or advanced age8 and pose a challenge
for intraoperative myocardial protection. Therefore
improved methods of cardioplegic protection are
required to lower the risks of surgery for these sub-
groups of patients.
Glucose-insulin-potassium solutions have been
commonly used to treat ischemic myocardium in a
variety of medical and surgical settings.9,10
Unfortunately, the results of earlier investigations
were often conflicting, and interest in metabolic stim-
ulation of the heart waned. One potential confounding
factor in the early studies of glucose-insulin-potassi-
um solutions was the routine use of moderate
hypothermic (25°C-28°C) cardiopulmonary bypass.
In retrospect, metabolic stimulation of the heart may
not have been effective at temperatures that inhibit
normal enzyme function. The advent of normother-
mic or warm heart surgery11 prompted renewed inter-
est in myocardial protection. We believe that a
reassessment of myocardial metabolic stimulation is
required at normothermic temperatures, which more
The contemporary results of coronary artery bypassgrafting are excellent with low overall morbidity and
mortality.1 However, as percutaneous2 and minimally
invasive3 approaches to the surgical treatment of coro-
nary artery disease become more common, the demo-
graphic profile of patients requiring conventional surgi-
cal revascularization will change. We have already
documented an increasing proportion of high-risk
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closely reflect current standards of practice and may
provide the most potential benefit.
In an earlier rodent study, Kobayashi and Neely12
demonstrated that the activity of a key mitochondrial
enzyme, pyruvate dehydrogenase (PDH), was inhibited
during early reperfusion after global ischemia. More
recent studies have demonstrated that the recovery of
postischemic myocardial function is dependent on the
recovery of PDH activity.13 We have recently reported
that insulin was capable of stimulating mitochondrial
PDH activity in isolated human ventricular cardiomyo-
cytes, which led to improved protection against
ischemia and reperfusion.14 We performed this
prospective, randomized, double-blind trial to deter-
mine whether insulin-enhanced cardioplegia conferred
similar metabolic or functional benefits to patients
undergoing coronary bypass surgery.
Methods
Patient population. Fifty-six male patients undergoing
isolated elective coronary bypass surgery consented to partic-
ipate in a metabolic evaluation of insulin-enhanced cardio-
plegia between September 1995 and July 1997. During this
interval, the study surgeon (R.D.W.) performed isolated coro-
nary bypass on 533 patients. A total of 477 patients were
excluded because of nonelective surgery (n = 303), redo
surgery (n = 21), or participation in alternative surgical trials
(n = 89). The remaining patients (n = 64) were deemed inel-
igible to participate because of female sex, diabetes mellitus,
recent preoperative infarction, significant left ventricular dys-
function (ejection fraction < 20%), or refusal to participate.
All patients signed an informed consent form approved by
our institutional ethics committee. The preoperative demo-
graphics for the study population are given in Table I.
Operative technique. All patients underwent coronary
revascularization by one surgeon (R.D.W.). The details of
anesthetic induction and intraoperative care have been previ-
ously described in detail.15 After anesthetic induction, the
patient was allocated to 1 of 4 cardioplegic groups deter-
mined by means of a computer-generated randomization
table (group 1, low glucose and placebo; group 2, low glu-
cose and insulin; group 3, high glucose and placebo; and
group 4, high glucose and insulin). Arterial blood was added
to crystalloid cardioplegic solution in a 4:1 ratio to achieve
Table I. Preoperative patient characteristics
Group 1 (n = 10) Group 2 (n = 12) Group 3 (n = 17) Group 4 (n = 17) P value
Age (y) 60 ± 8 64 ± 8 60 ± 9 60 ± 8 .54
LVEF
>60% 3 (30%) 1 (8%) 6 (35%) 8 (47%) .25
40%-59% 7 (70%) 11 (92%) 11 (65%) 8 (47%)
20%-39% 0 (0%) 0 (0%) 0 (0%) 1 (6%)
Triple vessel disease 8 (80%) 12 (100%) 14 (82%) 14 (82%) .40
Left main disease 0 (0%) 3 (25%) 2 (12%) 1 (6%) .24
PVD 0 (%) 1 (8%) 1 (6%) 0 (0%) .56
Hypertension 6 (60%) 7 (58%) 7 (41%) 7 (41%) .63
Group 1, 42 mmol/L glucose and no insulin; group 2, 42 mmol/L glucose and 10 IU/L insulin; group 3, 84 mmol/L glucose and no insulin; group 4, 84 mmol/L glu-
cose and 10 IU/L insulin; LVEF, left ventricular ejection fraction; PVD, peripheral vascular disease.
Table II. Perioperative data
Group 1 (n = 10) Group 2 (n = 12) Group 3 (n = 17) Group 4 (n = 17) P value
Grafts
3 2 (20%) 0 (0%) 2 (12%) 1 (6%) .13
4 3 (30%) 6 (50%) 2 (12%) 9 (53%)
5 5 (50%) 6 (50%) 13 (76%) 7 (41%)
XCL time (min) 70 ± 17 71 ± 15 75 ± 16 65 ± 14 .18
CPB time (min) 87 ± 18 92 ± 20 95 ± 18 85 ± 14 .41
Cardioplegia (L) 7 ± 3 7 ± 2 4 ± 3 5 ± 3 .89
Highest K+ level (mEq/L) 5.9 ± 0.5 5.4 ± 0.6 6.3 ± 0.5 5.4 ± 0.7 <.001
Perioperative MI 0 (0%) 1 (8%) 0 (0%) 0 (0%) .31
LOS 1 (10%) 1 (8%) 0 (0%) 0 (0%) .36
Length of stay (d) 7 ± 1 7 ± 2 7 ± 1 6 ± 1 .22
Mortality 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1.00
Group 1, 42 mmol/L glucose and no inulin; group 2, 42 mmol/L glucose and 10 IU/L insulin; group 3, 84 mmol/L glucose and no insulin; group 4, 84 mmol/L glu-
cose and 10 IU/L insulin; XCL, aortic crossclamp; CPB, cardiopulmonary bypass; MI, myocardial infarction; LOS, low-output syndrome.
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Fig 1. Arterial glucose concentrations in all 4 study groups.
The differences in arterial glucose observed during cardio-
plegic arrest dissipated within 2 hours of arrival into the ICU.
There were no overall differences in arterial glucose concen-
trations between groups. PRE, Prebypass; Xcl, aortic occlu-
sion; Xcl OFF, removal of crossclamp; CPB 10’, 10 minutes
after discontinuation of cardiopulmonary bypass; 5’, 10’, 2
HR, 4 HR, 8 HR, 24 HR, time after crossclamp removal.
the following final concentrations of all additives. On the
basis of our earlier findings and those of other investigators,
we chose to administer insulin (10 IU/L Humulin; Eli Lilly
Canada, Mississauga, Ontario, Canada) or placebo at two dif-
ferent ambient glucose concentrations9,14: a low-glucose con-
centration of 42 mmol/L and a high glucose concentration of
84 mmol/L. In addition to glucose, insulin, or both, all car-
dioplegic solutions contained equivalent concentrations of
potassium chloride (27 mEq/L for high K+ induction and 8
mEq/L for low K+ maintenance), magnesium sulphate (6
mEq/L for all solutions), tris(hydroxymethyl)amino methane
(125 mmol/L), and citrate-phosphate-dextrose (4 mmol/L).
The placebo was generously provided by Eli Lilly Canada
and contained the nonactive vehicle solution. The clinical
perfusionist responsible for the patient was the only individ-
ual aware of the randomization group and was responsible for
the preparation of all cardioplegic solutions. All other study
personnel, including the surgeon, remained blinded to the
randomization group.
After institution of cardiopulmonary bypass, all patients
received an antegrade induction dose (approximately 1000
mL) of tepid (29°C) high-potassium blood cardioplegic solu-
tion.15 After cardioplegic arrest, all patients received near-
continuous retrograde delivery of cardioplegic solution
through the coronary sinus. After completion of each distal
anastomosis, the proximal end of the vein graft was attached
to a cardioplegic manifold, enabling simultaneous delivery of
antegrade and retrograde blood cardioplegic solution.
Cardioplegic flow rates were maintained at 200 mL/min
unless the coronary sinus pressure rose above 40 mm Hg,
whereby the flow rate was adjusted accordingly.16 The flow
rate remained above 100 mL/min in all patients.17
Cardioplegic interruptions were limited to less than 7 min-
utes, and there were no more than 3 interruptions per patient.
During cardiopulmonary bypass, the systemic temperature
was allowed to drift to 32°C to 34°C. Rewarming to 37°C
was initiated during construction of the last distal vein graft
anastomosis.
To minimize contamination by exogenous insulin delivery,
a strict protocol was adopted for the treatment of intraopera-
tive hyperkalemia. An additional cardioplegic solution con-
taining identical additives to the randomization group with
the exception of potassium chloride was used initially if the
serum potassium level rose above 5 mmol/L with no evidence
of electrical activity. If the potassium level rose above 5.5
mmol/L, 10 or 20 mg of intravenous furosemide was given to
induce diuresis. If the serum potassium concentration rose
above 6.0 mmol/L, boluses of human insulin (Humulin; 5-10
IU) were given intravenously. In the event that patients
received exogenous insulin or glucose, they remained in their
initial randomization group consistent with an intent-to-treat
analysis.
After completion of all intraoperative biochemical
assessments, the patients were weaned from cardiopul-
monary bypass and transferred to the cardiac intensive care
unit (ICU). Postoperative ICU care was uniform in all
patients and followed an intention to extubate within 6
hours of arrival.18 Serial hemodynamic measurements were
obtained 2, 4, 8, and 24 hours after aortic crossclamp
removal, including heart rate, mean arterial pressure, pul-
monary capillary wedge pressure, central venous pressure,
and cardiac output. Cardiac index, left ventricular stroke
work index, and systemic vascular resistance were calcu-
lated by using standard formulas.15,16
Perioperative myocardial infarction and low cardiac output
syndrome were determined by means of previously estab-
lished criteria.1 In brief, the presence of a new Q wave or left
bundle branch block on the postoperative electrocardiogram
or a significant elevation of creatine kinase MB isoenzyme in
the presence of a pre-existing electrocardiographic abnormal-
ity was used to define a myocardial infarction. The require-
ment for intra-aortic balloon or sustained inotropic support
for greater than 30 minutes in the ICU defined the develop-
ment of low cardiac output syndrome. Patients who were
given low-dose dopamine (<5 µg · kg–1 · min–1) for renal per-
fusion were not considered to have low-output syndrome.
Biochemical assessments. Arterial and coronary sinus
blood samples were obtained at baseline, during each cardio-
plegic delivery, and at prespecified intervals during reperfu-
sion. In addition, a coronary sinus catheter was left in situ to
obtain postoperative blood samples 2, 4, 8, and 24 hours after
aortic crossclamp removal. Blood samples were assayed for
oxygen content, acid, pyruvate, and lactate concentrations
according to previously described protocols.15,16 Differences
between arterial and coronary sinus blood samples enabled us
to calculate myocardial extraction or release of these sub-
stances. During cardioplegic arrest, myocardial consumption,
or production was calculated after adjusting extraction-
release for coronary flow.
Statistical analysis. Statistical analysis was performed by
using the SAS analytic program (SAS Institute, Cary, NC).
Categoric data were analyzed by using the χ2 or Fisher exact
test as appropriate. Continuous data were analyzed by using
analysis of variance and are expressed as mean ± SD, unless
otherwise specified. Two-way repeated-measures analysis of
variance was used to analyze biochemical end points over
time. To correct for patient-specific activities of PDH, the
percentage recovery of PDH activity was calculated for each
patient, and the effects of time and group were assessed with
analysis of covariance. Hemodynamic data were analyzed by
means of analysis of covariance, examining the main effects
of time, group, and preload. Left ventricular preload was esti-
mated from measurements of pulmonary capillary wedge
pressure. Exact P values are reported to enable determination
of clinical and statistical significance.
Results
Operative data. Table II summarizes the perioperative
data for all 4 randomization groups. Randomization
groups were similar with respect to the number of distal
anastomoses performed, the mean aortic crossclamp and
cardiopulmonary bypass times, and the volume of car-
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Left ventricular biopsy specimens were obtained in 8
patients (glucose concentration of 84 mmol/L with or without
insulin; n = 4 each) for determination of myocardial PDH
activity. Full-thickness biopsy specimens were snap-frozen in
liquid nitrogen and then homogenized in 250 µL of phos-
phate-buffered saline solution (PBS). Mitochondrial PDH
activity was determined by a modification of a previously
described technique.14 In brief, 75-µL aliquots were divided
into separate Eppendorf tubes containing 75 µL of either PBS
or PBS with 5 mmol/L dichloroacetate. After a 10-minute
incubation at 37°C, the reaction was stopped with a buffer
solution containing 25 mmol/L sodium fluoride to inhibit
PDH phosphatase. Next, 50 µL from each Eppendorf tube
was exposed to 200 µL of reaction buffer containing 14C-
pyruvate. Protein content was simultaneously determined by
using a 100-µL aliquot from each Eppendorf tube assayed by
the Lowry method.14 The PDH reaction was then terminated
by using 100 µL of 10% trichloroacetic acid. Each Eppendorf
tube was then inserted into a scintillation vial containing 200
µL of benzothonium hydroxide. After exposure to each tissue
sample for 1 hour, the collected 14CO2 was then counted in aβ-counter. PDH activity was calculated after correction for
protein content and expressed as nanomoles of pyruvate oxi-
dized per milligram of protein per minute.
Fig 2. Intraoperative myocardial lactate flux. Cardioplegic arrest induced significant anaerobic lactate release in
all patients. Over time, there were no significant effects of either glucose concentration (upper panel, P = .83) or
insulin (lower panel, P = .28) on myocardial lactate flux. However, immediately after crossclamp removal,
patients who received insulin cardioplegia demonstrated lactate extraction compared with persistent anaerobic
lactate release in the placebo groups (P = .03 by using the Student t test). PRE, Prebypass; XCL, aortic occlusion;
OFF, removal of crossclamp; LAST, final cardioplegic dose.
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Fig 3. Effects of glucose (upper panel) and insulin (lower panel) on intraoperative myocardial oxygen extraction.
During the crossclamp period, there was a significant interactive effect between glucose and insulin (P = .03).
During reperfusion, myocardial oxygen extraction returned to baseline in the insulin cardioplegia groups.
However, there was increased oxygen extraction in the placebo groups, suggestive of repayment of an oxygen
debt. There was no significant effect of glucose concentration (P = .33); however, there was a significant insulin
effect over time (insulin·time effect, P = .04). PRE, Prebypass; XCL, aortic occlusion; OFF, removal of cross-
clamp; LAST, final cardioplegic dose.
dioplegic solution delivered. There were no differences in
the times of cardioplegic interruption expressed as a per-
centage of the total crossclamp time (P = .6). However,
patients exposed to insulin cardioplegia at either ambient
glucose concentration had a lower peak serum potassium
level than patients in groups 1 and 3 (P < .001). Persistent
hyperkalemia required insulin boluses in 6 patients
(11%), 5 who received placebo and 1 who received
insulin cardioplegia (P = .07). Hypoglycemia requiring
supplemental dextrose administration occurred in 5
patients, 3 of whom received insulin and high-glucose
cardioplegia. The remaining 2 patients received low-glu-
cose cardioplegia with placebo. Interestingly, there was
no observed hypoglycemia in the low-glucose (42
mmol/L) and insulin groups. Fig 1 illustrates arterial glu-
cose levels, which were similar in all 4 study groups dur-
ing the experimental protocol.
There was no mortality in this study population.
There was 1 patient in group 2 who had a perioperative
myocardial infarction and had postoperative low car-
diac output syndrome. One additional patient in group
1 had low-output syndrome without evidence of infarc-
tion. The postoperative length of stay was similar in all
4 groups. No permanent neurologic deficits were
observed in any patients, including the 5 patients who
had hypoglycemia.
Biochemical outcomes. Fig 2 demonstrates the effects
of glucose (upper panel) and insulin (lower panel) on
myocardial lactate release during the surgical procedure.
There were no significant effects of glucose (P = .8) or
insulin (P = .3) over time. During the crossclamp period,
there were no differences between groups in myocardial
lactate production (corrected for coronary blood flow).
However, at crossclamp removal, patients who received
insulin-enhanced cardioplegic solution displayed a posi-
tive lactate flux (P = .03 by the Student t test) compared
with a negative flux in those who received placebo, sug-
gesting better aerobic metabolism.
The Journal of Thoracic and
Cardiovascular Surgery
Volume 119, Number 6
Rao et al 1181
Fig 3 demonstrates the effects of glucose (upper
panel) and insulin (lower panel) on myocardial oxygen
extraction during the surgical procedure. During the
crossclamp period, there was a significant interactive
effect between glucose and insulin (P = .03). When cor-
rected for coronary blood flow, myocardial oxygen
consumption was affected by both ambient glucose
concentration and insulin (glucose · insulin effect, P =
.07). During reperfusion, myocardial oxygen extraction
returned to baseline in the insulin cardioplegia groups.
However, there was increased oxygen extraction in the
placebo groups, suggestive of repayment of an oxygen
debt. There was no significant effect of glucose con-
centration (P = .33); however, there was a significant
insulin effect over time (insulin · time effect, P = .04).
Fig 4 demonstrates the activity of mitochondrial PDH
measured just before cardioplegic arrest, at the end of
the crossclamp period, and after 10 minutes of reperfu-
sion. There was a significant effect of cardioplegic
arrest on myocardial PDH activity (time effect, P =
.009). During the crossclamp period, PDH activity rose
to near maximal levels; however, this activation was
attenuated during early reperfusion. We were unable to
demonstrate an insulin effect on myocardial PDH activ-
ity at any time point (group effect, P = .5)
Hemodynamic outcomes. Table III provides the raw
hemodynamic data for all 4 groups. Fig 5 demonstrates
the improvement in left ventricular performance seen in
the insulin cardioplegia groups 2 hours after surgery.
Both cardiac index and left ventricular stroke work
index were greater in the insulin cardioplegia groups at
similar filling pressures. Insulin-enhanced cardioplegia
induced a significant vasodilatory effect, as evidenced
by the lower systemic vascular resistance compared
with the placebo groups.
Discussion
Coronary bypass surgery continues to be associated
with low morbidity and mortality despite an increasing
proportion of high-risk patients.4 Although a wide variety
of myocardial protective strategies may be successful in
low-risk patients with preserved left ventricular function,
cardioplegic additives may be required for those patients
who have acute ischemic syndromes or impaired left ven-
tricular function. We have previously demonstrated that
cardioplegic interventions that yield metabolic and func-
tional benefits in low-risk patients produce improvements
in morbidity and mortality in high-risk subgroups.19 We
designed this prospective randomized study to determine
the metabolic and functional effects of glucose and
insulin in low-risk patients undergoing isolated coronary
Fig 4. Myocardial PDH activity (nanomoles per milligrams per
minute) before cardioplegic arrest (PRE), just before aortic
crossclamp removal (XCL), and after 10 minutes of reperfusion
(OFF). PDH activity increased during cardioplegic arrest but
returned to baseline values during early reperfusion (time
effect, P = .009). There were no significant effects of either
glucose or insulin on PDH activity (group effect, P = .48).
Fig 5. Cardiac index (upper panel) and left ventricular stroke
work index (lower panel) at 2 hours after surgery. Patients
who received insulin cardioplegia demonstrated enhanced
left ventricular performance compared with placebo at simi-
lar filling pressures. PCWP, Pulmonary capillary wedge pres-
sure. Circles represent low-glucose cardioplegia, squares rep-
resent high-glucose cardioplegia, open symbols represent
placebo groups, and closed symbols represent insulin groups.
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bypass surgery with a strategy of tepid antegrade-retro-
grade blood cardioplegia.
Biochemical response to glucose and insulin.
Patients in groups 2 and 4 (insulin-enhanced cardiople-
gia) received approximately 60 U of short-acting
human insulin during 1 hour of cardioplegic arrest.
Despite this large dose of insulin, there were no signif-
icant differences in arterial glucose concentrations in
the early postoperative period. This is likely because of
the short half-life of insulin in blood combined with
our approach of direct myocardial delivery. Adding
insulin to the crystalloid component of the cardioplegic
solution resulted in a first-pass effect, whereby insulin
was directly exposed to myocardial receptors before
venous drainage from the right atrium. We believe that
this mode of delivery is inherently safer than systemic
delivery through a central vein. Only 5 patients
required supplemental glucose, and of these, only 2 had
severe hypoglycemia (<3 mmol/L). There were no
adverse neurologic outcomes in any of the 4 study
groups.
Our previous cellular studies indicated that insulin
was capable of stimulating myocardial PDH activity.14
The theoretic benefit of PDH stimulation involves an
earlier transition from anaerobic to aerobic metabolism
after an ischemic insult. Weiss and Hiltbrand20 report-
ed that adenosine triphosphate produced by oxidative
phosphorylation was preferentially used for contractile
function compared with anaerobically produced adeno-
sine triphosphate, which was used for membrane sta-
bility.20 Furthermore, Lewandowski and White13
demonstrated that postischemic left ventricular func-
tion was dependent on the recovery of PDH activity.
Unfortunately, we were unable to detect an insulin
effect on the activity of myocardial PDH. Although
cardioplegic arrest and reperfusion greatly influenced
the activity of PDH, our small sample size did not
allow us to detect a significant stimulatory effect of
insulin. However, myocardial oxygen consumption was
higher during cardioplegic arrest in the insulin groups,
suggesting enhanced aerobic activity. Although the
placebo group demonstrated repayment of an oxygen
debt during early reperfusion, myocardial oxygen
extraction was similar to baseline in the insulin cardio-
plegia groups. Although there appeared to be an insulin
effect during cardioplegic arrest, the differences in
myocardial PDH activity failed to achieve statistical
significance, probably because of the small number of
patients who had biopsies. Myocardial lactate flux was
not affected by cardioplegia group, although at one
Table III. Postoperative hemodynamic data
Group 1 (n = 10) Group 2 (n = 12) Group 3 (n = 17) Group 4 (n = 17) P value
2 h
Heart rate (beats/min) 80 ± 12 82 ± 12 85 ± 19 89 ± 22 .71
PCWP (mm Hg) 14 ± 2 12 ± 1 12 ± 1 13 ± 1 .53
Cardiac index (L/min) 2.4 ± 0.2 3.0 ± 0.1 2.6 ± 0.2 3.2 ± 0.3 .01
LVSWI (g·m–1·m–2) 25 ± 2 31 ± 2 25 ± 2 31 ± 2 .08
SVRI 2571 ± 224 1790 ± 102 1962 ± 228 1715 ± 165 .01
4 h
Heart rate (beats/min) 90 ± 10 78 ± 12 87 ± 19 84 ± 18 .26
PCWP (mm Hg) 17 ± 2 15 ± 1 14 ± 2 15 ± 1 .61
Cardiac index (L/min) 2.4 ± 0.1 2.5 ± 0.1 3.0 ± 0.2 2.8 ± 0.2 .07
LVSWI (g·m–1·m–2) 24 ± 3 26 ± 2 29 ± 1 28 ± 3 .34
SVRI 2444 ± 165 2053 ± 128 1913 ± 217 1922 ± 186 .10
8 h
Heart rate (beats/min) 86 ± 13 84 ± 15 90 ± 12 86 ± 15 .84
PCWP (mm Hg) 16 ± 2 13 ± 1 14 ± 1 12 ± 2 .38
Cardiac index (L/min) 2.7 ± 0.1 2.8 ± 0.2 2.7 ± 0.2 2.7 ± 0.2 .81
LVSWI (g·m–1·m–2) 26 ± 3 29 ± 2 30 ± 2 25 ± 1 .44
SVRI 2001 ± 174 1982 ± 102 2507 ± 292 1920 ± 129 .14
24 h
Heart rate (beats/min) 90 ± 11 79 ± 13 85 ± 15 86 ± 17 .31
PCWP (mm Hg) 13 ± 2 11 ± 1 13 ± 2 13 ± 2 .64
Cardiac index (L/min) 2.8 ± 0.2 2.8 ± 0.2 2.6 ± 0.1 2.7 ± 0.1 .70
LVSWI (g·m–1·m–2) 31 ± 3 31 ± 3 27 ± 2 29 ± 2 .75
SVRI 2301 ± 176 1922 ± 90 2069 ± 88 2108 ± 137 .22
Group 1, 42 mmol/L glucose and no insulin; group 2, 42 mmol/L glucose and 10 IU/L insulin; group 3, 84 mmol/L glucose and no insulin; group 4, 84 mmol/L glu-
cose and 10 IU/L insulin; PCWP, Pulmonary capillary wedge pressure; LVSWI, left ventricular stroke work index; SVRI, systemic vascular resistance index.
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time point (crossclamp removal) the insulin-enhanced
groups demonstrated greater lactate flux, again sugges-
tive of improved aerobic capacity. In previous cell cul-
ture studies, we found that insulin resulted in higher
PDH activity after 30 minutes of reperfusion.14 In this
protocol we assessed PDH activity at 10 minutes of
reperfusion. Similar to the results obtained from
Kobayashi and Neely,12 we found an inhibition of PDH
activity in the early postischemic period. We hypothe-
size that the improvements in left ventricular perfor-
mance observed in the insulin cardioplegia groups are
a result of enhanced myocardial PDH activity at 2
hours of reperfusion.
Hemodynamic effects. Although we were unable to
detect major biochemical differences between groups,
we did demonstrate a significant hemodynamic benefit
in the insulin cardioplegia groups. Both cardiac index
and stroke work index were higher in the insulin car-
dioplegia groups at similar filling pressures. This
hemodynamic benefit was evident 2 hours after surgery
but dissipated by the eighth postoperative hour. There
was a marked reduction in systemic vascular resistance
in the insulin cardioplegia group, an effect previously
reported by other investigators.21 The combination of
increased inotropy with decreased afterload may prove
to be most efficacious in patients with poor ventricular
function. We are presently completing a clinical trial to
evaluate the salutatory effects of insulin in this high-
risk population.
Summary
This prospective study was designed to evaluate the
effects of insulin and glucose as cardioplegic additives on
the recovery of myocardial metabolism and function after
elective coronary bypass surgery. Insulin-enhanced car-
dioplegia demonstrated both metabolic and functional
benefit independent of the ambient glucose concentra-
tion. Because of the possible deleterious effects of hyper-
glycemia on postoperative neurologic outcomes,22 we
recommend a low-glucose cardioplegic formulation, even
when insulin is used as an additive. The potential clinical
benefits of insulin-enhanced cardioplegia will require fur-
ther investigation in high-risk subgroups of patients
undergoing myocardial revascularization.
We thank the clinical perfusionists and the nursing staff of
the Cardiovascular Intensive Unit of the Toronto General
Hospital for their assistance in completing this study.
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Insulin Cardioplegia Trial (ICT) investigators
Steering Committee. George T. Christakis, MD; Joan
Ivanov RN, MSc; C. David Naylor, MD, DPhil; Vivek Rao,
MD, PhD; Richard D. Weisel, MD.
Trial Coordinators. Michael A. Borger, MD; Susan M.
Carson, AHT; Gideon Cohen, MD; Vania DeSouza, MD;
Barbara Weller, RN.
Safety and Outcomes Committee. Davey Cheng, MD; Jacek
Karski, MD; Keyvan Kartoukian, MD; C. David Mazer, MD;
Terry M. Smith, MD; Bill I. Wong, MD; Terrence M. Yau, MD.
Biochemical Support. Frank Merante, PhD; Donald A. G.
Mickle, MD; Molly K. Mohabeer; Laura C. Tumiati.
Participating Surgeons. Gopal Bhatnagar, MD; Daniel
Bonneau, MD; George T. Christakis, MD; Robert J.
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Christopher M. Feindel, MD; Stephen E. Fremes, MD;
Bernard S. Goldman, MD; Lynda L. Mickleborough, MD;
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Hugh E. Scully, MD; Glen S. Van Arsdell, MD; Richard D.
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Commentary
Rao and associates are to be congratulated for carry-
ing out a rare feat in cardiac surgery, a prospective ran-
domized trial comparing two surgical therapeutic
options. This randomized trial of 56 patients undergo-
ing coronary bypass grafting with continuous tepid car-
dioplegia demonstrated that the addition of insulin in
the cardioplegic solution decreased initial systemic
vascular resistance, increased early cardiac output and
stroke work, decreased serum potassium levels, and
improved early cardiac lactate extraction. The authors
concluded that insulin cardioplegia improved myocar-
dial metabolic and functional recovery.
The reasons for few randomized surgical trials are
many. When cardiac function is the end point, detecting
subtle differences in cardiac function can be very diffi-
cult during concurrent changes in cardiac load. In this
study the authors were fortunate that the treatment
group had lower cardiac afterload and similar cardiac
preload, while having increased stroke work. Had after-
load increased, it might have been difficult to deter-
mine whether increased stroke work was caused by
increased contractility or by increased afterload.
Like any good study, this one raises several questions
that remain to be answered:
1. Do the beneficial effects of insulin cardioplegia in
continuous tepid cardioplegia also apply to intermittent
cold cardioplegia? Today, intermittent cold cardiople-
gia is far more commonly used than continuous tepid
cardioplegia. The authors suggest that insulin may in
fact not be beneficial in intermittent cold cardioplegia.
Previous research looking at glucose-insulin-potassium
cardioplegia never conclusively found benefit in cold
intermittent cardioplegia. The reason may be, as the
authors suggest, that insulin may overcome a block in
mitochondrial glucose metabolism at the level of pyru-
vate dehydrogenase at warmer temperatures, although
not at colder temperatures where enzyme activities
may be markedly different. If so, the value of this study
will await greater evidence concerning the practicality
and benefits of warm tepid cardioplegia over intermit-
tent cold cardioplegia.
2. Given the relatively short 2-hour duration of bene-
fits realized from insulin cardioplegia in this study, are
these benefits great enough to be of any consequence?
Perhaps the benefit may be greater in the small number
of cases in which myocardial protection may still be
suboptimal with current techniques (ie, those with
longer ischemic times [especially cardiac transplanta-
tion] or those with poor baseline ventricular function).
The applicability of continuous tepid cardioplegia to
longer ischemic times needs to be demonstrated, given
that metabolic demands will also be greater at tepid
temperatures than at colder temperatures. Are the total
potassium loads of continuous tepid cardioplegia over
longer ischemic times adequately tolerated by patients,
particularly in patients with baseline renal insufficiency?
3. As in point 1 above, what precisely is the mecha-
nism by which insulin benefits the heart in continuous
tepid cardioplegia? The answer to this may help to clar-
ify the role of insulin in cold intermittent cardiology.
This study by Rao and associates will certainly need
to be confirmed by other investigators in other settings
before insulin can be considered a standard additive to
continuous tepid cardioplegia. In the interim, the rela-
tively clear and positive results of this study should
encourage other cardiac surgical investigators to con-
sider prospective randomized trials. Studies like this
could avoid years of heated debate in interpreting large
amounts of data that are more easily obtained but of
much lower quality.
Donald D. Glower, MD
Durham, North Carolina
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